News

Jones Soda to sparkle on retail shelves

BY Ryan Chavis

SEATTLE — Jones Soda Co. announced the launch of Jones Sparkling Water, which was created in response to consumer demand for healthier products.
 
Jones Sparkling Water is available in four flavors — Berry Lemonade, Fufu Berry, Green Apple and Strawberry Lime — and is packaged in 8-oz. cans, making it an ideal addition to school lunchboxes and family trips, the company said. The beverage has no added sweeteners, no added colors and no artificial preservatives. 
 
“We are bringing fun into this exploding sparkling water category, and in a unique way that appeals to kids,” says Jones Soda CEO, Jennifer Cue. “This is something we are all proud to stand behind. As the mother of a 7 year old, I can identify with parents who are looking for something interesting, fun and healthful to give to their kids for lunches, or really anytime. With fun, natural flavors, no added sugar or preservatives and no added colors, Jones Sparkling Water is a great way to encourage our young children to drink more healthy beverages.”
 

Jones Sparkling Water will first be available in a four-pack at Target stores in the West and Mountain regions, as well as online at JonesSoda.com. The product is expected to become available at other retailers across the United States in the near futuer, the company said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Celgene’s Otezla approved to treat plaque psoriasis

BY Ryan Chavis

SUMMIT, N.J. — Celgene Corp. earlier this week announced that the Food and Drug Administration approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis. The drug is the first and only PDE4 inhibitor approved for the treatment of plaque psoriasis, according to the company. Otezla was approved on March 21, 2014 by the FDA for treatment of active psoriatic arthritis. 
 
“Otezla offers an important new treatment option for patients whose symptoms are not adequately improving with their current treatments. In clinical trials, Otezla reduced redness, thickness and scaliness of plaques in patients with moderate or severe plaque psoriasis,” said Dr. M. Shane Chapman, section chief of dermatology at Dartmouth-Hitchcock Medical Center. “Because the product labeling does not require routine laboratory monitoring, oral Otezla may be a welcome new option for patients and physicians looking for a different treatment experience.”
 
Otezla is available in the United States and is dispensed through a network of specialty pharmacies. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

FDA approves new indication for Humira

BY Ryan Chavis

NORTH CHICAGO, Ill. — AbbVie on Thursday announced that the Food and Drug Administration approved Humira (adalimumab) as a treatment for pediatric Crohn's disease patients ages 6 years and older when other treatments haven't worked well enough. The agency's approval marks the eighth indication for the drug in the United States.
 
"Moderate to severe Crohn's disease is a serious chronic disorder that can impact children and adolescents in significant ways during this important stage of their lives," said Jeffrey S. Hyams, M.D., head, division of digestive diseases, hepatology and nutrition, Connecticut Children's Medical Center. "The approval of Humira for this patient population offers a new important treatment option for physicians and their patients that can help address this sometimes debilitating disease."
 
Humira can be self-administered after proper injection training and with appropriate physician monitoring. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?